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Abstract
Objectives: We sought to evaluate the prescribing pattern of statins according to national and regional health policy
interventions and to assess specifically the adherence to the therapy in outpatient setting in Southern Italy.
Methods: A population-based study was performed on persons $15 years old, living in the catchment area of Caserta
(Southern Italy), and registered in Arianna database between 2004 and 2010. Prevalence and incidence of new treatments
with statins were calculated for each year and stratified by drug. Adherence to therapy was measured by Medication
Possession Ratio. Sub-analyses by individual compound and type of cardiovascular prevention were performed.
Results: From 2004 to 2010, the one-year prevalence of statin use increased from 44.9/1,000 inhabitants to 79.8/1,000,
respectively, consistently with the incidence of new use from 16.2/1,000 to 19.5/1,000, except a slight decrease after criteria
reimbursement revision on 2005 (13.3/1,000). The incidence of new treatments decreased for atorvastatin, and increased for
simvastatin over the study years. Overall, 43% of new users were still highly adherent to the treatment (MPR$80%) after six
months, while 26% after 4-years of follow-up. As compared with highly adherent patients, the probability to be non-
adherent (MPR#25%) at 4-years of follow-up was 26% higher for women than for men (full adj. odds ratio: 1.26; 95% CI:
1.10–1.45), and 64% higher in patients who started on primary rather than on secondary prevention (1.64; 1.29–2.07).
Conclusions: Prevalence and incidence of statin use increased consistently with health policy interventions. Only one-fourth
of patients who newly initiated a statin were adherent to the treatment after 4-year of follow-up. Since the benefits of
statins in terms of cardiovascular outcome and costs are associated with their chronic use, the identification of patient-
related predictors of non-adherence such as gender, primary prevention could be suitable for physicians to improve the
patients’ compliance.
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Introduction
Cardiovascular diseases (CVDs) represent one of the primary
cause of mortality in Western countries, accounting for 54% of all
deaths in women and 43% of all deaths in men [1]. The role of
hypercholesterolemia as cardiovascular risk factor is well-recog-
nised, thus the introduction of lipid-lowering treatment with statins
has represented one of the most important achievement of the
recent medicine. In the last decade, the use of statins is widely
increased in both United States and European countries because
of the large body of evidence demonstrating their effectiveness in
the cardiovascular prevention, both in subjects with or without
history of CVD [2]. In particular, between 2003 and 2011, the use
of these drugs showed a positive trend in Italy, representing also, in
the last year of this period, the drug class with the highest
expenditure (16.4 euro per capita) in Italy [3]. To optimize the use
of lipid-lowering drugs, in 2004 the Italian Medicine Agency
(Agenzia Italiana del Farmaco, AIFA) revised the reimbursement
criteria (NOTA 13), according to which the purchase of statins was
reimbursed by the National Health Service either for primary
prevention in patients with familial hypercholesterolemia/hyper-
lipidaemia, those with 10-years risk of CVD .20% (based on
national risk charts) or for secondary prevention, in subjects with
previous well-established cardiovascular or cerebrovascular events,
including patients affected by diabetes mellitus [4,5]. As a
consequence of the above national health policy intervention, in
Campania region, in November 2008 a regional health policy
intervention encouraging the prescription of two statins with
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expired patent, simvastatin or pravastatin, in new users with high
cardiovascular risk was issued. A secondary aim of this interven-
tion was to promote the adherence to the treatment with the
ultimate goal to fully achieve the benefits of statin therapy [6].
In spite of the increased use of statins worldwide, recent findings
documented the poor adherence to these drugs in the general
population [7–10]. Adherence to medications has been associated
with improved outcomes in coronary artery disease [11]. Further
evidence suggested that, in general, improved adherence to a
number of chronic disease medications, e.g. antidiabetic drugs,
may also reduce overall healthcare costs [12]. The importance of
adherence to statin therapy for primary or secondary prevention is
well-documented. To date, reliable predictors of non-adherence to
statin treatment have not clearly established [13]. Since very low
adherence to treatment may reduce protective effects of statins, it
could be useful to readily recognise such predictors to improve the
level of adherence and consequently the effectiveness of statin
treatment [14].
For this reason, we explored the healthcare record database
from Local Health Unit of Caserta, in Campania region (Southern
Italy), to describe the prescription pattern of statins in primary care
setting, in relation to national and regional health policy
interventions. Then, we assessed statin-specific rate and predictors
of poor adherence to treatment in the same population.
Materials and Methods
Data source
This retrospective, drug utilization study was performed
retrieving data from the Arianna database during the years
2004–2010. The database, which was set up by the Local Health
Service of Caserta in the year 2000, currently contains information
on almost 400,000 individuals living in the catchment area of
Caserta and registered on the lists of 289 GPs. Collected
information included patients’ demographic characteristics and
drug prescription without charge classified according the Ana-
tomical Therapeutic Chemical (ATC) classification system, linked
to medical diagnoses coded by the International Classification of
Disease, 9th revision, Clinical Modification (ICD-9). This database
allowed us to anonymously track clinical and drug history
routinely collected for each patient. All GPs enrolled in the
Arianna database had previously been trained in data collection
techniques. Among 289 GPs, only 120 met eligible criteria for
quality assessment of data collection during the study period. Data
quality and completeness have been already validated in previous
drug-utilization studies, ensuring that Arianna database is an
evaluable data source to estimate the effect of national and local
health-policy intervention [15–24].
Study population
We retrieved data on all individuals aged 15 years and over who
were registered in the lists of 120 validated GPs during the years
2004–2010. Among those, we identified patients who received at
least one prescription of statin during the observation years. Statin
therapy could be likewise initiated by GPs or specialists (in this case
passing by GP to get the prescription reimbursed by National
Health System). Demographic and clinical characteristics of each
user, with specific focus on statin therapy (e.g. type of statin,
indications and type of prevention) and concomitant diseases were
also retrieved. A treatment was defined as secondary prevention if
the statin user was affected by coronary heart disease, cerebro-
vascular disease, peripheral arterial disease, CV procedures, or
diabetes mellitus anytime prior to the prescription of statin [20].
Study drugs
Use of the following statins was explored: simvastatin (ATC:
C10AA01), lovastatin (C10AA02), pravastatin (C10AA03), fluvas-
tatin (C10AA04), atorvastatin (C10AA05), rosuvastatin
(C10AA07), and fixed combination simvastatin-ezetimibe
(C10BA02).
Data analysis
Yearly prevalence of statin treatment was measured as the ratio
between the number of patients who received at least one
prescription and the number of individuals alive and registered in
the GPs’ list in each study year. To evaluate the yearly incidence of
statin use (cumulative incidence) we defined a new user as a patient
receiving a first statin prescription within the observation year
without any statin prescription recorded in the previous year. For
each year, the cumulative incidence was calculated as the ratio
between the number of new users and the number of individuals
alive and registered in the GPs’ lists, without any statin
prescription in the previous year. Both, yearly- prevalence and
incidence of statin use were stratified by gender and reported as
rate per 1,000 inhabitants, together with 95% confidence interval
(CI). Furthermore, cumulative incidence was stratified by single
compound, and calendar year and characteristics of new users
were evaluated according to the type of prevention.
A subgroup analysis was performed among newly initiated statin
therapy with at least 6 months of follow-up to assess the adherence
to the therapy at months 6, 12, 18, 24, 30, 36, 42 and 48 after start
of the therapy. The Medication Possession Ratio (MPR) was
calculated as the proportion of the number of pills supply
dispensed over the intended period of statin treatment (in months).
By assuming a single intake per day, the number of pills
corresponded to the numbers of days for which the patient had
been prescribed with statins [25]. For instance, in a period of 180
days, four dispensings of 30 pills’ supply (i.e, 120 days) of
rosuvastatin would result in an estimated MPR of 67% (120/180).
MPR was categorised into 4 levels of adherence: very low (MPR#
25%), low (MPR=26%–50%), intermediate (MPR=50%–80%)
and high adherence (MPR$80%) [26]. Because prescriptions
filled was used as a proxy for beneficiary status, users with a
MPR#25% were considered as non-adherent to statin therapy,
while a MPR$80% was established as threshold for adherence
[27].
To investigate the potential predictors of non-adherence
(defined as very low adherence) to statin therapy at 4-years of
follow-up, we performed a sub-analysis restricted to two groups of
patients: those with either very low or high levels of adherence to
statin therapy at month 48.
Statistical analysis
Chi-square for trend was used to evaluate the variation in 1-year
prevalence or incidence of statin use during the observation
period.
Two-tailed chi–squared test for proportion with significance
level of P,0.05 was used for assessing the baseline characteristics
of new users of different statins according to the type of
prevention.
To identify predictors of non-adherence (i.e. very low adher-
ence) to statin therapy after 4-years from the start of the treatment,
univariate logistic regression model using high adherence as
comparator was carried out. All the covariates significantly
associated with the non-adherence in the first model have been
included in the full adjusted model of multivariate logistic
regression. Odds Ratios (ORs) plus CI 95% were measured for
each covariate of interest.
Use and Adherence to the Statin Treatment
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Ethics
Local Health Service of Caserta provided for anonymised
patient records information and approved the use of data for this
analysis. Data are not available for public sharing because of
privacy reasons.
Results
Out of 155,316 individuals who were registered on the GPs’ lists
during the observation period of seven years, we identified 15,877
patients who had received at least one prescription for statin.
Among the prevalent users, we observed a similar distribution in
terms of gender (8,071 women vs. 7,806 men) with a mean age of
63.7611.5 years (data not shown).
Yearly-prevalence and incidence of statin treatment
Yearly-prevalence of statin use significantly increased from 44.9
(95% CI: 43.7–46.1)/1,000 inhabitants in 2004 to 79.8 (78.3–81.2)
in 2010. Among women, the prevalence progressively increased
from 43.9 (42.3–45.5) to 75.7 (73.7–77.6), except for a slight
decrease in 2005, and among men increased linearly from 46.0
(44.3–47.7) to 84.3 (82.1–86.5). Except for 2004, the prevalence of
statin use was significantly higher among men than women during
the entire study period (P,0.05) (Figure 1).
Yearly-incidence of statin use decreased from 16.2/1,000 (15.5–
16.9) in 2004 to 13.3/1,000 (12.7–13.9) in 2005, while the
situation has reversed thereafter, and the incidence rose to 19.5/
1,000 (18.7–20.2) in 2010. No statistically significant differences by
gender were reported among new users of statins during the study
period, except in 2005 when we observed a larger reduction of the
incidence in women (12.0; 11.2–12.9) than in men (14.7; 13.8–
15.7) (Figure 2).
Looking at single compounds, the incidence of atorvastatin use
decreased from 6.0/1,000 (5.6-6.4) in 2004 to 4.5/1,000 (4.1–4.8)
in 2010. An increased trend of new use of simvastatin was
observed, with the incidence equal to 3.7/1,000 (3.4–4.1) in 2004,
which was slightly decreased to 2.4/1,000 (2.1–2.7) in 2006, and
increased up to 8.9/1,000 (8.4–9.4) in 2010 (Figure 3).
Characteristics of new users of statins
A total of 12,980 users who newly initiated a treatment with
statin were identified during the seven-years study period.
Demographic and clinical characteristics of new users of statins
by type of cardiovascular prevention is reported in Table 1.
Mean age was 63.5 years (SD611.8), with statin users treated for
primary prevention who were predominantly women (57.6% vs.
42.4%, women vs. men) and significantly younger than those
receiving statins for secondary prevention (60.2 vs. 65.5 years; P,
0.01). In both types of prevention, however, women were
significantly older than men (P,0.01).
Significant differences in burden of comorbidities at time of the
first prescription were observed between primary and secondary
prevention statin treatment. Specifically, the proportions of
hyperlipidaemia was significantly higher in primary prevention
treatment than in secondary prevention (91.3% vs. 60.6%
respectively; P,0.01). On the contrary, more patients on
secondary prevention than on primary had hypertension (76.3%
vs. 61.8%) and other cardiovascular risk factors (21.9% vs. 15.4%).
With regard to the specific compound, simvastatin, atorvastatin,
rosuvastatin and pravastatin were the most frequently prescribed
statins as first-line treatment, irrespective of the type of prevention.
Atorvastatin was significantly more commonly used for secondary
than primary prevention (29.5% vs 21.8%), while simvastatin, the
combination simvastatin-ezetimibe and lovastatin were significant-
ly more frequently prescribed for primary than secondary
prevention (36.1% vs 32.8%; 2.4% vs 0.9%; 8.6% vs 7.0%
respectively).
Adherence to statin treatment
Among new users with at least 6 months of follow-up, the
proportion of patients who had high level of adherence to statin
treatment significantly decreased along 4-years of follow-up,
ranging from 43.1% at month 6 of therapy to 26.1% at month
48 (Table 2). Predictive factors of very low adherence after 4
years from the start of the statin therapy are reported in Table 3.
As compared to those with high adherence, patients with a very
low adherence were more likely to be women (OR 1.42; CI 95%
1.24–1.62) and to be treated as primary prevention (1.84; 1.60–
2.12). Consistently with the type of prevention, presence of
cardiovascular or cerebrovascular diseases or diabetes mellitus was
Figure 1. Yearly prevalence of statin use/1,000 inhabitants stratified by calendar year and gender.
doi:10.1371/journal.pone.0102146.g001
Use and Adherence to the Statin Treatment
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inversely associated with very low adherence. As compared to
atorvastatin use, simvastatin (1.91; 1.61–2.27), pravastatin (1.79;
1.43–2.25), fluvastatin (1.41; 1.06–1.88) and lovastatin (1.77; 1.31–
2.39) use was significantly associated to higher risk of very low
adherence to the treatment. Full adjusted model confirmed the
results from the main analysis for women, patients in primary
prevention, or users of simvastatin, pravastatin, fluvastatin and
lovastatin as predictive factors of non-adherence (Table 3).
Discussion
Our population-based drug-utilization study focused on the
change in the GPs’ behaviour on prescribing patter of statin in a
primary care database of Southern Italy according to the health
policy interventions, both national and regional. Moreover, the
results of this study identified several factors as predictors of non-
adherence to the treatment, that is generally frequent in newly
prescribed patients [28].
As expected, yearly-prevalence of statin use has almost doubled
from 2004 to 2010. This is in accordance to previous studies that
found a constantly growing use of statins in most European
countries since their marketing [29,30], including Italy [3,31–37].
Several studies explored the prescribing pattern of statins in
different Italian regional settings [19,38]. In particular, a study
performed in Northern Italy over a 10-year period (1994–2003)
reported a 28% average increase per year [39]. As well-
documented, the rapid increase of statin use is attributable to
several factors, including the rising awareness of the evidence-
based effectiveness of these drugs, the government policies
promoting more aggressive management of cardiovascular risk
factors, and an increase of life expectancy in patients with CVD.
Despite of this overall increasing trend, we observed no change
of prevalence in 2005. This result is in line with the health policy
intervention issued on November 2004 by AIFA that revised the
reimbursement criteria of statins by introducing the evaluation of
cardiovascular risk charts in the management of dyslipidaemia
[5,40]. The impact of this regulatory action was confirmed in our
analysis of the yearly-incidence of statin use, which significantly
decreased in 2005, specifically for women. Indeed, these risk charts
led to a reduction in statin use according to the fact that Italian
population is thought to have relatively lower cardiovascular
mortality than other countries [29]. Moreover, this reduction was
mainly related to women on the basis of scientific evidence
supporting that cardiovascular risk factors affect more men than
women [41,42]. This peculiar trend was already reported in a
study that explored statin utilization in the same setting but over a
shorter period of observation (2003–2005) [19]. Because our data
cover a longer period of time, we were able to analyze the long-
Figure 2. Yearly incidence of statin use/1,000 inhabitants stratified by calendar year and gender.
doi:10.1371/journal.pone.0102146.g002
Figure 3. Yearly incidence of statin use stratified by individual compound.
doi:10.1371/journal.pone.0102146.g003
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term effect of this intervention, in terms of management of
dyslipidaemic patients according to these new cardiovascular risk
charts. Thus, as expected, the incidence of statin use progressively
rose from 2006 until 2008, year of the disclosure of new regional
policy intervention in Campania Region [6]. The Delibera
Regionale, in order to stimulate diagnostic and therapeutic
appropriateness in terms of cost-efficacy, stated that the prescrip-
tion of statins in new users should be considered only after three
months-period of diet, physical activity or smoke discontinuation.
In addition, when starting a new treatment, the use of one the two
free of patent statins, simvastatin and pravastatin, should be
preferred in patients with high cardiovascular risk [6]. The impact
of this policy intervention is reflected on no variation in the yearly-
incidence of overall statin use observed over two years 2008–2009,
followed by an increase thereafter. Moreover, this influence was
even more evident in terms of single statin use. Interestingly, as
prompt response from GPs to the regional policy, the incidence of
use per 1,000 inhabitants on 2009 drastically decreased for
atorvastatin and rosuvastatin while increased for simvastatin and
pravastatin.
According to the type of prevention, although the point
prevalence and incidence of statin use were lower for women
than for men, there were more women than men in terms of the
absolute number of newly initiated treatment anytime in our
observation period. Surprisingly, the proportion of women was
higher in primary than in secondary prevention. This is
noteworthy because current evidence of lipid-lowering from
clinical trials showing that women are relatively protected from
cardiovascular events until menopausal age, support the use of
statins on secondary prevention in women with previous coronary
diseases [43,44]. Nevertheless, since some recent evidence showed
similar results to our study [45], it could imply that the focus on
cardiovascular risk treatment in women is rising in the most recent
years [46]. However, in terms of age, our results showing that
Table 1. Baseline characteristics of new users of statins by type of prevention.
Total Primary prevention Secondary prevention P value
n=12,980 (%) n=4,811 (%) n=8,169 (%)
Gender ,0.01
Women 6,673 (51.4) 2,773 (57.6) 3,900 (47.7)
Men 6,307 (48.6) 2038 (42.4) 4,269 (52.3)
Mean age, y (±SD) 63.5 (11.8) 60.2 (12.3) 65.5 (11.0) ,0.01
Mean age by gender, y (±SD) ,0.01
Female 65.4 (11.2) 62.2 (11.4) 67.6 (10.5)
Male 61.5 (12.0) 57.4 (12.8) 63.5 (11.0)
Age category (in years) ,0.01
15–44 784 (6.0) 516 (10.7) 268 (3.3)
45–54 2,002 (15.4) 938 (19.5) 1,064 (13.0)
55–64 3,869 (29.8) 1,533 (31.9) 2,336 (28.6)
.65 6,325 (48.7) 1,824 (37.9) 4,501(55.1)
Comorbidity
Hyperlipidaemia 9,348 (72.0) 4,394 (91.3) 4,954 (60.6) ,0.01
Hypertension 9,207 (70.9) 2,975 (61.8) 6,232 (76.3) ,0.01
Diabetes mellitus 4,125 (31.8) - 4,125 (50.5)
Cardiovascular events* 3,991 (30.7) - 3,991 (48.9)
Other cardiovascular risk factors# 2,526 (19.5) 741 (15.4) 1,785 (21.9) ,0.01
Cerebrovascular events 1,445 (11.1) - 1,445 (17.7)
Peripheral arterial disease 1,189 (9.2) - 1,189 (14.6)
Renal failure 225 (1.7) 77 (1.6) 148 (1.8) 0.37
Statin Type
Simvastatin 4,412 (34.0) 1,736 (36.1) 2,676 (32.8) ,0.01
Atorvastatin 3,457 (26.6) 1,047 (21.8) 2,410 (29.5) ,0.01
Rosuvastatin 2,001 (15.4) 750 (15.6) 1,251 (15.3) 0.67
Pravastatin 1,430 (11.0) 547 (11.4) 883 (10.8) 0.32
Lovastatin 984 (7.6) 416 (8.6) 568 (7.0) ,0.01
Fluvastatin 510 (3.9) 201 (4.2) 309 (3.8) 0.26
Simvastatin-Ezetimibe 186 (1.4) 114 (2.4) 72 (0.9) ,0.01
Values are shown as number (%) of new users, except where otherwise specified.
*Cardiovascular events include coronary heart disease, acute myocardial infarction,.
#Other cardiovascular risk factors include cardiomyopathies, valve disorders, arrhythmias, or atrial flutter/fibrillation, heart failure, or congenital heart disease.
Abbreviations: y = years; SD = Standard Deviation.
doi:10.1371/journal.pone.0102146.t001
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women that newly initiated a statin medication are significantly
older than men are consistent with previous investigations [44].
Looking at comorbidity history, we observed several differences
among people starting on primary or secondary prevention, with
more individuals with hyperlipidaemia or hypertension on primary
prevention treatment and more patients with other cardiovascular
risk factors, like arrhythmias valves disorders, cardiomyopathies or
heart failure on secondary prevention treatment.
With regard to individual medications, simvastatin, atorvastatin,
rosuvastatin and pravastatin, were the most frequently prescribed
statins as a first-line treatment, irrespective of the type of
prevention, in line with previous investigations [19,30], but in
contrast with the latest Italian National Reports of medication use
(OSMED) which identified atorvastatin as the most prescribed
statin in Italy, followed by rosuvastatin and simvastatin [3,36,37].
The discrepancies across national and regional settings could be
explained by the clinical impact of the regional policy intervention
promoting the use of statins free of patent, as simvastatin and
pravastatin. This result is, as described above, more evident from
the analysis of the incidence stratified by calendar year and
molecules, which showed an increase of new use of these two
statins after 2008. On the other hand, the heterogeneity between
results from our study and from OSMED could be due to different
methodological measure of prescriptions as OSMED explored
prevalent and naive users of statins while we focused only on naive
users [3,31–37].
Stratifying by the type of prevention, atorvastatin was signifi-
cantly more prescribed for secondary prevention than for primary.
A recent meta-analysis on comparative benefits of statins on major
cerebrovascular events suggested that, although any statin therapy
is associated with a significant reduction in cerebrovascular events
in secondary prevention, only atorvastatin resulted in significantly
fewer events than controls [47]. On the contrary, simvastatin and
lovastatin were prescribed mainly for primary prevention.
Nevertheless, there are no recommendations supporting the
preferential use of a particular statin for primary or secondary
prevention [48].
Despite several randomized controlled clinical trials have shown
that only a continuous treatment with statins is effective in
achieving a reduction of cardiovascular morbidity and mortality,
as pointed out by the Delibera Regionale, we found that less than
50% of patients who newly initiated a statin were still adherent to
the treatment (with MPR$80%) after six months of follow-up,
with a further reduction to 26% after 4-year of follow-up. This
data are consistent with previous investigations that suggested a
poor level of adherence to statin treatment and, consecutively, a
reduction of long-term effectiveness. Looking at the predictive
factors of non-adherence after 4-years from the start of the statin
therapy, the probability to be non-adherent was 26% higher for
women than for men, suggesting that women have lower perceived
risk of disease. Moreover, patients on primary prevention had 64%
higher probability to be non-adherent than those on secondary. In
line with previous studies performed in similar Italian settings, our
data suggested that starting a statin for secondary prevention
seems to be predictive factor for higher long-term adherence. This
could be explained by the hypothesis that, while the healthiest
people has a minor perception of the risk, less-healthy people (i.e.
patients with history of CVD) are strongly motivated, by GPs or by
themselves, to continue the therapy to achieve the therapeutic goal
[49,50]. In addition, the use of simvastatin, pravastatin, fluvastatin
or lovastatin as first line therapy seems to predict higher
probability to be non-adherent as compared to atorvastatin.
There is no previous evidence to explain these results; the higher
use of atorvastatin in secondary prevention could partially explain
this evidence. Moreover, since the discontinuation of treatment, as
defined for MPR calculation, does not consider if a patient
switched across statins, we cannot exclude that people starting with
simvastatin, pravastatin, fluvastatin or lovastatin could have
changed the type of statin as consequence of the occurrence of
adverse effects or as lack of efficacy. To date, lack of efficacy and
drug therapeutic failure (DTF) are included within the wider
definition of adverse drug event given by the World Health
Organisation (WHO) and it is proposed as a peculiar type of
adverse drug reaction designated as ‘‘Failure’’ [51–53]. However,
since healthcare providers may have a crucial impact on patients’
adherence to medication, the identification of these patient-related
predictors for non-adherence could be useful to increase the
compliance.







Very low (MPR#25%) Low (MPR=26–50%) Intermediate (MPR=50–80%) High (MPR$80%)
n (%) n (%) n (%) n (%)
6 12,235 2,531 (20.7) 2,329 (19.0) 2,099 (17.2) 5,276 (43.1)
12 11,081 3,380 (30.5) 1,649 (14.9) 1,998 (18.0) 4,054 (36.6)
18 10,232 3,292 (32.2) 1,578 (15.4) 1,931 (18.9) 3,431 (33.5)
24 9,352 3,244 (34.7) 1,321 (14.1) 1,838 (19.7) 2,949 (31.5)
30 8,554 3,019 (35.3) 1,274 (14.9) 1,692 (19.8) 2,569 (30.0)
36 7,527 2,665 (35.4) 1,221 (16.2) 1,488 (19.8) 2,153 (28.6)
42 6,644 2,399 (36.1) 1,130 (17.0) 1,250 (18.8) 1,865 (28.1)
48 5,749 2,178 (37.9) 973 (16.9) 1,097 (19.1) 1,501 (26.1)
*only new users with at least 6 months of follow-up have been included in this analysis.
#adherence to therapy was assessed by MPR (Medical Possession Ratio) as the ratio between the number of pills supply of medication dispensed and the intended
period of statin treatment (in months). This indicator was categorised into 4 coverage groups: very low (MPR #25%); low (MPR= 26%–50%); intermediate (MPR = 50–
80%); High (MPR$80%).
doi:10.1371/journal.pone.0102146.t002
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Strengths and limitations
This drug-utilization study aimed to measure the use of statin in
a general practice of southern Italy. The availability of prescription
data over a seven-year period (2004–2010) allowed us to evaluate
the implications of nationwide and regionwide health policy
interventions in the real clinical practice. Finally, very long
observation period and availability of many variables routinely
collected through this healthcare record database provide insight
into long-term adherence to statin therapy. Several limitations of
our study warrant caution. First of all, we used outpatient
prescription data, and we had no information whether prescrip-
tions were actually filled. Nevertheless, since our study was aimed
to evaluate the GPs’ prescribing behaviour according to health
policy interventions, this prescription database can be considered
suitable for such investigation. However, only less than half of all
the GPs enrolled in the Arianna database previously trained in
data collection techniques. This could represent a potential
information bias reducing the sensitivity to investigate the
prescribing trend of statins. On the other hand, the accuracy of
these high-qualified GPs ensured an high specificity in order to
explore the predictive factors of non-adherence, likewise to
previously published studies showing that the Arianna database
provides accurate and reliable information on drug utilization and
is an evaluable data source to estimate the effect of national and
local health-policy intervention [15–18]. Second, our data did not
allow us to explore other potential predictors of non-adherence,
such as smoking, overweight/obesity, cholesterolemia, liver
enzymes or Creatine Phosphokinase levels, which are not routinely
collected in the database. Finally, we used Medication Possession
Ratio (MPR) as an adherence measure. Discontinuation might
fulfil only part of the full definition of non-adherence, which,
moreover, includes very low adherence, intermittent use and
switch between statins.
Conclusions
The increase prevalence and incidence of statin use across
2004–2010 in Southern Italy was consistent with the trend
observed in other national and regional settings, as validation of
such database for observational studies. Moreover, the identifica-
tion of several patient-related predictors for non-adherence (such
Table 3. Predictive factors at 4-year follow-up of very low adherent (n= 2,178) compared to high adherent (n= 1,501) to the statin
treatment.
Very low adherent* High adherent* OR& (95% CI) P value ORadjusted
&(95% CI) P value
n=2,178 (%) n=1,501 (%)
Gender
Men 1,005 (46.1) 824 (54.9) ref. ref.
Women 1,173 (53.9) 677 (45.1) 1.42 (1.24–1.62) ,0.01 1.26 (1.10–1.45) ,0.01
Prevention type
Secondary 1,244 (57.1) 1,066 (71.0) ref. ref.
Primary 934 (42.9) 435 (29.0) 1.84 (1.60–2.12) ,0.01 1.64 (1.29–2.07) ,0.01
Comorbidity history
$
Hyperlipidaemia 1743 (80.0) 981 (65.4) 2.12 (1.83–2.47) ,0.01 1.79 (1.53–2.11) ,0.01
Hypertension 1518 (69.7) 1029 (68.6) 1.05 (0.91–1.21) 0.46 -
Diabetes mellitus 649 (29.8) 495 (33.0) 0.86 (0.75–0.99) 0.04 1.14 (0.94–1.37) 0.18
Cardiovascular events 642 (29.5) 599 (39.9) 0.63 (0.55–0.72) ,0.01 0.99 (0.82–1.20) 0.91
Other cardiovascular risk factors# 414 (19.0) 263 (17.5) 1.10 (0.93–1.31) 0.25 —
Cerebrovascular events 212 (9.7) 182 (12.1) 0.78 (0.63–0.95) 0.02 0.99 (0.78–1.26) 0.90
Peripheral arterial disease 189 (8.7) 136 (9.1) 0.95 (0.76–1.20) 0.69 -
Renal failure 42 (1.9) 19 (1.3) 1.53 (0.89–2.65) 0.13 -
Statin therapy
Atorvastatin. 631 (29.0) 591 (39.4) ref. ref.
Simvastatin 677 (31.1) 332 (22.1) 1.91 (1.61–2.27) ,0.01 1.92 (1.63–2.27) ,0.01
Rosuvastatin 281 (12.9) 241 (16.1) 1.09 (0.89–1.34) 0.40 -
Pravastatin 293 (13.5) 153 (10.2) 1.79 (1.43–2.25) ,0.01 1.77 (1.42–2.21) ,0.01
Fluvastatin 142 (6.5) 94 (6.3) 1.41 (1.06–1.88) 0.01 1.35 (1.01–1.79) 0.04
Lovastatin 144 (6.6) 76 (5.1) 1.77 (1.31–2.39) ,0.01 1.72 (1.28–2.32) ,0.01
Simvastatin-Ezetimibe 10 (0.5) 14 (0.9) 0.67 (0.29–1.51) 0.34 -
*Adherence level was categorized according to the MPR: very low (MPR#25%); high (MPR$80%).
&Odds Ratio as measure of probability of being very low adherent to the statin treatment compared the users being high adherent. All the covariates significantly
associated with the non-adherence in the first model have been included in the full adjusted model.
#Other cardiovascular risk factors include cardiomyopathies, valve disorders, arrhythmias, or atrial flutter/fibrillation, heart failure, or congenital heart disease.
$
Absence of comorbidity as reference.
.Users of atorvastatin have been defined as reference group because atorvastatin resulted the most prescribed statins in this specific subcohort of analysis and, overall,
in Italy, as reported in OSMED; in addition, the choice is consistent with a previous published study on predictors of adherence [3,28,36,37]
Abbreviations: MPR: Medication Possession Ratio; OR =Odds Ratio; CI = confidence interval.
doi:10.1371/journal.pone.0102146.t003
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as gender and primary prevention) to the treatment could be
suitable for GPs to improve their patients’ behaviours. These data
provide evidence for a good general practice in Southern Italy
according to the health policy interventions either national or
regional, issued to promote the appropriateness of the statin
prescription. However, on 2011 AIFA revised again the statin
reimbursement criteria (NOTA 13) in light of updated scientific
evidence. Further long-term follow-up studies, starting from 2012,
need to be performed to explore the long-term clinical impact of
this intervention.
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